Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novozymes A/S Comments on FY 2013 Guidance


Friday, 25 Oct 2013 02:00am EDT 

Novozymes A/S announced that it has decided to narrow the guidance for the fiscal year 2013 within the existing ranges, following the performance for nine months in line with expectations, and to reflect the unfavorable development in exchange rates since previous guidance. Organic sales growth is now expected at 5-7%, sales growth in local currency at 6-8% and sales growth in DKK at 3-5%. EBIT growth is now expected at 4-5%, and the outlook for EBIT margin has increased to 24-25%. Net profit growth is now expected at 7-8%. For the fiscal year 2012, the Company reported revenue of DKK 11,234 million, EBIT of DKK 2,745 million and Net Income of DKK 2,015 million. 

Company Quote

50.55
0.17 +0.34%
2:52pm EDT